Literature DB >> 21420406

The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.

Lisa A Kilpatrick1, Jennifer S Labus, Kristen Coveleskie, Christian Hammer, Gudrun Rappold, Kirsten Tillisch, Joshua A Bueller, Brandall Suyenobu, Johana M Jarcho, Jim A McRoberts, Beate Niesler, Emeran A Mayer.   

Abstract

BACKGROUND & AIMS: 5-Hydroxytryptamine (5-HT)3 receptor (5-HT3R) antagonists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effects. Their therapeutic effects are related, in part, to reducing amygdala engagement during expected visceral pain. A single nucleotide polymorphism in HTR3A, c.-42C>T;(C178T; rs1062613), is associated with altered reactivity of the amygdala during emotional face processing in healthy subjects (controls). We evaluated the influence of this single nucleotide polymorphism on amygdala reactivity to emotional faces and nonemotional stimuli in female patients with IBS and controls.
METHODS: We measured brain responses during an affect-matching paradigm in 54 women (26 with IBS, 29 controls) using functional magnetic resonance imaging. We examined associations between HTR3A c.-42C>T genotype (C/C vs T carrier) and responses in amygdala and other regions of brain that expressed high levels of 5-HT3R.
RESULTS: The C/C genotype was associated with greater anxiety symptoms in patients with IBS and controls and increased activation of the amygdala under emotional and nonemotional conditions. Among patients with IBS, C/C genotype was associated with greater symptom ratings. A subset of IBS patients with the C/C genotype had increased amygdala responses to nonemotional stimuli, compared with other subjects with C/C genotype.
CONCLUSIONS: Regardless of diagnosis, the C/C genotype of the c.-42C>T polymorphism in HTR3A, compared with T carrier status, is associated with increased anxiety and amygdala responsiveness during emotional and nonemotional tasks. This polymorphism was associated with severity of IBS symptoms. Although this genotype is not sufficient for diagnosis of IBS, it is associated with severity of symptoms.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420406      PMCID: PMC3757951          DOI: 10.1053/j.gastro.2011.03.011

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  49 in total

1.  Presynaptic 5-HT3 receptor-mediated modulation of synaptic GABA release in the mechanically dissociated rat amygdala neurons.

Authors:  S Koyama; N Matsumoto; C Kubo; N Akaike
Journal:  J Physiol       Date:  2000-12-01       Impact factor: 5.182

2.  Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

Authors:  G J Kilpatrick; B J Jones; M B Tyers
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

Review 3.  The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?

Authors:  Ramamoorthy Rajkumar; Radhakrishnan Mahesh
Journal:  J Psychopharmacol       Date:  2010-02-01       Impact factor: 4.153

Review 4.  Molecular biology of 5-HT receptors.

Authors:  Jason Hannon; Daniel Hoyer
Journal:  Behav Brain Res       Date:  2008-03-25       Impact factor: 3.332

5.  Regulation of anxiety by GABAA receptors in the rat amygdala.

Authors:  S K Sanders; A Shekhar
Journal:  Pharmacol Biochem Behav       Date:  1995-12       Impact factor: 3.533

6.  Distribution of neurons expressing immunoreactivity for the 5HT3 receptor subtype in the rat brain and spinal cord.

Authors:  M Morales; E Battenberg; F E Bloom
Journal:  J Comp Neurol       Date:  1998-12-21       Impact factor: 3.215

7.  First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome.

Authors:  Johannes Kapeller; Lesley A Houghton; Hubert Mönnikes; Jutta Walstab; Dorothee Möller; Heinz Bönisch; Barbara Burwinkel; Frank Autschbach; Benjamin Funke; Felix Lasitschka; Nikolaus Gassler; Christine Fischer; Peter J Whorwell; Wendy Atkinson; Catherine Fell; Karl J Büchner; Marco Schmidtmann; Ivo van der Voort; Anna-Sophia Wisser; Thomas Berg; Gudrun Rappold; Beate Niesler
Journal:  Hum Mol Genet       Date:  2008-07-09       Impact factor: 6.150

8.  Relationship between anxiety and gastric sensorimotor function in functional dyspepsia.

Authors:  Lukas Van Oudenhove; Joris Vandenberghe; Brecht Geeraerts; Rita Vos; Philippe Persoons; Koen Demyttenaere; Benjamin Fischler; Jan Tack
Journal:  Psychosom Med       Date:  2007-06-07       Impact factor: 4.312

9.  Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders.

Authors:  Christian Hammer; Johannes Kapeller; Max Endele; Christine Fischer; Johannes Hebebrand; Anke Hinney; Susann Friedel; Mònica Gratacòs; Xavier Estivill; Manfred Fichter; Fernando Fernández-Aranda; Stefan Ehrlich; Gudrun Rappold; Beate Niesler
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

10.  Calcium influx through presynaptic 5-HT3 receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies.

Authors:  T J Turner; D J Mokler; J I Luebke
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

View more
  40 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.

Authors:  A P Rajkumar; B Poonkuzhali; A Kuruvilla; A Srivastava; M Jacob; K S Jacob
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 3.  Pharmacogenetics and the treatment of functional gastrointestinal disorders.

Authors:  Houssam Halawi; Michael Camilleri
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

4.  Association of genetic polymorphisms in HTR3A and HTR3E with diarrhea predominant irritable bowel syndrome.

Authors:  Qiao-Yan Gu; Jun Zhang; Yi-Chao Feng; Guang-Rong Dai; Wei-Ping Du
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 5.  The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Authors:  Yang Won Min; Poong-Lyul Rhee
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

6.  Neuroimaging the brain-gut axis in patients with irritable bowel syndrome.

Authors:  Kristen R Weaver; LeeAnne B Sherwin; Brian Walitt; Gail D'Eramo Melkus; Wendy A Henderson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

Review 7.  Irritable bowel syndrome.

Authors:  Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller
Journal:  Nat Rev Dis Primers       Date:  2016-03-24       Impact factor: 52.329

Review 8.  Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety.

Authors:  Esther Asan; Maria Steinke; Klaus-Peter Lesch
Journal:  Histochem Cell Biol       Date:  2013-03-15       Impact factor: 4.304

Review 9.  Genetics of human gastrointestinal sensation.

Authors:  M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2013-04-17       Impact factor: 3.598

10.  Evidence for alterations in central noradrenergic signaling in irritable bowel syndrome.

Authors:  Steven Berman; Brandall Suyenobu; Bruce D Naliboff; Joshua Bueller; Jean Stains; Heng Wong; Mark Mandelkern; Leah Fitzgerald; Gordon Ohning; Arpana Gupta; Jennifer S Labus; Kirsten Tillisch; Emeran A Mayer
Journal:  Neuroimage       Date:  2012-08-21       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.